News

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!”

The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate, from waste in order to reduce microplastics pollution. Ourobio converts whey into PHB through a biochemical process.

Ourobio was voted “shark favorite” out of nine entrepreneurs in Richmond business accelerator Lighthouse Labs’ 2022 spring cohort that pitched to four business leaders as part of the accelerator’s biannual Demo Day competition May 24. Ourobio received $1,500 from sponsor ThinkNimble and will have naming rights to a tagged great white shark that Lighthouse Labs is sponsoring.

Founded in 2012, Lighthouse Labs is a mentor-driven nonprofit accelerator that runs two, 12-week cohort sessions each year, investing $20,000 equity-free in six to 10 early-stage startups. Entrepreneurs accepted into the program receive mentorship and education on scaling up their businesses. Lighthouse Labs has accelerated more than 80 companies during the last 10 years, providing more than $1.6 million in equity-free funding. The Demo Day pitch contest is the grand finale event for each cohort.

Llamawood CEO Hunter Garen won the audience vote in the Demo Day competition; for his prize, he was given the privilege of throwing the first pitch at a Richmond Flying Squirrels baseball game.

While the same may not be true for his throwing arm,  Garen started his business pitch with a flourish, tossing postcards with coupon codes into the first few rows. Llamawood connects firewood suppliers and purchasers.

“I designed for a woman … because, as they say, women’s standards are much higher than men’s, so if you design for a woman, you’ll make every man happy,” Garen joked when telling the sharks about his customer demographics.

Sharks judging the competition were: Ajay Kori of UrbanStems and Novilla Pharmaceuticals; Claire Herring of Blue Ocean Brain; Richard Wintsch of Startup Virginia; and Joy Polefrone with VCU Health.

Also pitching at the competition were founders of Richmond-based beauty company LipLoveLine; Philadelphia-based software manufacturer Viora Health; Fort Belvoir-based health tech company Kinometrix Inc.; Philadelphia-based health care tech firm Hoth Intelligence; Richmond-based Nessle, which operates an online platform for expectant  parents; Austin, Texas-based tech firm On-Time Trials; and Houston-based health care tech company CaseCTRL.

Read more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and